INSYS Therapeutics Inc. (INSY)

0.88
NASDAQ : Health Technology
Prev Close 0.82
Day Low/High 0.83 / 0.92
52 Wk Low/High 0.79 / 11.65
Avg Volume 1.15M
Exchange NASDAQ
Shares Outstanding 74.57M
Market Cap 61.26M
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Insys Therapeutics (INSY) Is Today's Strong On High Volume Stock

Insys Therapeutics (INSY) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Insys Therapeutics (INSY) as a strong on high relative volume candidate

RBC Capital Markets Says Buy These 5 Pharmaceutical Stocks, Despite 'Irrational' Sell Off

RBC Capital Markets Says Buy These 5 Pharmaceutical Stocks, Despite 'Irrational' Sell Off

The selloff in specialty pharmaceutical stocks has found a new 'irrational low,' following Wednesday's attack on Valeant Pharmaceuticals, according to RBC Capital Markets.

Insys Therapeutics (INSY) Is Today's Dead Cat Bounce Stock

Insys Therapeutics (INSY) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Insys Therapeutics (INSY) as a "dead cat bounce" (down big yesterday but up big today) candidate

Weak On High Volume: Insys Therapeutics (INSY)

Weak On High Volume: Insys Therapeutics (INSY)

Trade-Ideas LLC identified Insys Therapeutics (INSY) as a weak on high relative volume candidate

Jim Cramer's 'Mad Money' Recap: Seeing a Double Standard in Market Valuations

Jim Cramer's 'Mad Money' Recap: Seeing a Double Standard in Market Valuations

Cramer says Apple is in a tug of war between the bull and bears, and the bears seem to be winning.

Biotech Stock Mailbag: Alzheimer's Conference Preview, Why Stock Prices Sometimes Lie

Biotech Stock Mailbag: Alzheimer's Conference Preview, Why Stock Prices Sometimes Lie

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Trade-Ideas: Insys Therapeutics (INSY) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Insys Therapeutics (INSY) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Insys Therapeutics (INSY) as a strong on high relative volume candidate

Water-Logged And Getting Wetter: Insys Therapeutics (INSY)

Water-Logged And Getting Wetter: Insys Therapeutics (INSY)

Trade-Ideas LLC identified Insys Therapeutics (INSY) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Marijuana Stocks and the Risks of a '420 Friendly' Portfolio

Marijuana Stocks and the Risks of a '420 Friendly' Portfolio

Want to invest in marijuana stocks? You'd better do your homework first -- otherwise, you might get burned.

'Mad Money' Lightning Round: Buy, Buy, Buy Citigroup

'Mad Money' Lightning Round: Buy, Buy, Buy Citigroup

Cramer says he wouldn't mind owning Caterpillar, is waiting on Alcoa and is sticking with Cypress Semiconductor.

Jim Cramer's 'Mad Money' Recap: Here's Why We Had a Rally Today

Jim Cramer's 'Mad Money' Recap: Here's Why We Had a Rally Today

The Federal Reserve statement, Greece, selling the dollar and investor confidence all had a hand, Cramer says.

Strong On High Relative Volume: Insys Therapeutics (INSY)

Strong On High Relative Volume: Insys Therapeutics (INSY)

Trade-Ideas LLC identified Insys Therapeutics (INSY) as a strong on high relative volume candidate

Insider Trading Alert - TNAV, INSY And PEG Traded By Insiders

Insider Trading Alert - TNAV, INSY And PEG Traded By Insiders

Stocks with insider trader activity include TNAV, INSY and PEG

Insider Trading Alert - INSY, HF And NEWT Traded By Insiders

Insider Trading Alert - INSY, HF And NEWT Traded By Insiders

Stocks with insider trader activity include INSY, HF and NEWT

Insider Trading Alert - REXI, MNTX And INSY Traded By Insiders

Insider Trading Alert - REXI, MNTX And INSY Traded By Insiders

Stocks with insider trader activity include REXI, MNTX and INSY

5 Hated Earnings Stocks You Should Love

5 Hated Earnings Stocks You Should Love

These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.

'Mad Money' Lightning Round: Kinder Morgan, HCA Are Winners

'Mad Money' Lightning Round: Kinder Morgan, HCA Are Winners

Cramer says to be careful on Insys Therapeutics, prefers Starbucks over Dunkin Brands and would buy Alaska Air.

Jim Cramer's 'Mad Money' Recap: Get Ready for a Rough Ride

Jim Cramer's 'Mad Money' Recap: Get Ready for a Rough Ride

Supply is the true enemy of the bull and there's a lot of new supply hitting the markets, Cramer says.

Insider Trading Alert - INSY, SYNT And ASGN Traded By Insiders

Insider Trading Alert - INSY, SYNT And ASGN Traded By Insiders

Stocks with insider trader activity include INSY, SYNT and ASGN

Russell Flexes Its Muscles

Market has timid reaction to Tuesday's slide.

Commit To Purchase Insys Therapeutics At $50, Earn 22.6% Annualized Using Options

Commit To Purchase Insys Therapeutics At $50, Earn 22.6% Annualized Using Options

Investors considering a purchase of Insys Therapeutics Inc shares, but cautious about paying the going market price of $57.96/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $50 strike, which has a bid at the time of this writing of $5.10.

Insider Trading Alert - INSY, LNKD And IMPV Traded By Insiders

Insider Trading Alert - INSY, LNKD And IMPV Traded By Insiders

Stocks with insider trader activity include INSY, LNKD and IMPV

INSY: Insiders vs. Shorts

INSY: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 10/31/2014 settlement date, and Insys Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 15.41 "days to cover" versus the median component at 5.75. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Insys Therapeutics (INSY) Upgraded From Hold to Buy

Insys Therapeutics (INSY) Upgraded From Hold to Buy

Insys Therapeutics (INSY) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BAK, CAR, CIA, FSM, INSY, MORN, NMRX, OPLK, ORA, PNX, RGP, UFS Downgrades: BBLU, BREW, CKEC, FRM, HK, VALE Initiations: MGNX, OCIP Read on to get TheStreet Quant Ratings' detailed report:

Insys Therapeutics (INSY) Is Weak On High Volume Today

Insys Therapeutics (INSY) Is Weak On High Volume Today

Trade-Ideas LLC identified Insys Therapeutics (INSY) as a weak on high relative volume candidate

Insys Therapeutics (INSY) Stock Soars Today on Third Quarter Earnings Beat

Insys Therapeutics (INSY) Stock Soars Today on Third Quarter Earnings Beat

Insys Therapeutics (INSY) stock is sharply up this morning, after the company reported better than expected third quarter earnings results.

Insys Therapeutics (INSY) Marked As A Dead Cat Bounce Stock

Insys Therapeutics (INSY) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Insys Therapeutics (INSY) as a "dead cat bounce" (down big yesterday but up big today) candidate

Insys Therapeutics (INSY) Marked As A Dead Cat Bounce Stock

Insys Therapeutics (INSY) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Insys Therapeutics (INSY) as a "dead cat bounce" (down big yesterday but up big today) candidate

Weak On High Volume: Insys Therapeutics (INSY)

Weak On High Volume: Insys Therapeutics (INSY)

Trade-Ideas LLC identified Insys Therapeutics (INSY) as a weak on high relative volume candidate

TheStreet Quant Rating: D (Sell)